Skandinaviska Enskilda Banken (SEB)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,100	Closed	-$563K	–	1212
2020 Q4	$563K	Sell	12,100 -5,200	-30%	-$243K	﹤0.01%	897
2020 Q3	$735K	Sell	17,300 -17,100	-50%	-$748K	0.01%	782
2020 Q2	$1.65M	Buy	34,400 +900	+3%	+$44.9K	0.01%	620
2020 Q1	$1.54M	Sell	33,500 -800	-2%	-$40.1K	0.02%	542
2019 Q4	$2.06M	Buy	34,300 +300	+0.9%	+$17.9K	0.02%	557
2019 Q3	$1.92M	Sell	34,000 -5,500	-14%	-$309K	0.02%	557
2019 Q2	$2.2M	Sell	39,500 -16,500	-29%	-$861K	0.02%	484
2019 Q1	$2.83M	Buy	56,000 +3,700	+7%	+$165K	0.03%	392
2018 Q4	$2.11M	Buy	52,300 +7,700	+17%	+$397K	0.02%	462
2018 Q3	$3.09M	Buy	+44,600	New	+$3.38M	0.02%	390

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s EGRX Position: Q1 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 12,100 shares — an estimated $563K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in EGRX in Q3 2018 and held it in 10 quarters. The position peaked at $3.09M in Q3 2018. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

Skandinaviska Enskilda Banken (SEB) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 12,100 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $563K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 10 quarters.
Skandinaviska Enskilda Banken (SEB)'s Eagle Pharmaceuticals, Inc. position peaked at $3.09M in Q3 2018.
155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2021, filed 14 May 2021.